Last €9.34 EUR
Change Today +0.113 / 1.23%
Volume 50.0
LZ1 On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 2:04 PM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).

momenta pharmaceuticals inc (LZ1) Snapshot

Open
€9.26
Previous Close
€9.22
Day High
€9.51
Day Low
€9.25
52 Week High
01/17/14 - €14.38
52 Week Low
10/13/14 - €7.27
Market Cap
495.3M
Average Volume 10 Days
158.5
EPS TTM
--
Shares Outstanding
53.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MOMENTA PHARMACEUTICALS INC (LZ1)

momenta pharmaceuticals inc (LZ1) Related Businessweek News

No Related Businessweek News Found

momenta pharmaceuticals inc (LZ1) Details

Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs. The company’s complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a glatiramer acetate injection indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis. Its biosimilars programs include M923 and M834, which are biosimilars for autoimmune and inflammatory diseases; and M511, a monoclonal antibody for oncology. The company’s novel products comprise M402, a novel oncology drug candidate that is in a Phase 1/2 clinical study, which binds to various growth factors, adhesion molecules, and chemokines to inhibit tumor progression, metastasis, and angiogenesis; and the sialylation technology that is a discovery program of a mixture of human immunoglobulin G antibodies for the treatment of inflammatory diseases. It has collaboration and license agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

269 Employees
Last Reported Date: 02/28/14
Founded in 2001

momenta pharmaceuticals inc (LZ1) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $621.0K
Co-Founder, Chief Scientific Officer and Seni...
Total Annual Compensation: $387.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $362.5K
Senior Vice President and President of Biosim...
Total Annual Compensation: $19.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $395.7K
Compensation as of Fiscal Year 2013.

momenta pharmaceuticals inc (LZ1) Key Developments

Momenta Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Fourth Quarter and Second Half of 2014

Momenta Pharmaceuticals Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company has posted total collaboration revenue was $9,336,000 against $10,751,000 a year ago. Operating loss was $29,275,000 against $25,661,000 a year ago. Net loss was $29,101,000 or $0.56 basic and diluted per share against $25,382,000 or $0.50 basic and diluted per share a year ago. For the nine months, the company has posted total collaboration revenue was $31,071,000 against $22,716,000 a year ago. Operating loss was $83,257,000 against $79,257,000 a year ago. Net loss was $82,619,000 or $1.61 basic and diluted per share against $78,347,000 or $1.54 basic and diluted per share a year ago. The company confirmed its financial guidance for the second half of 2014: the company previously projected that total 2014 operating expenses, excluding stock-based compensation and net of collaborative revenues, would be $28 to $30 million per quarter and, in the first three quarters of 2014, the average amount per quarter was $30 million. For the fourth quarter of 2014, the company projects total operating expenses, excluding stock-based compensation and net of collaborative revenues, to be $30 to $32 million. The company previously projected that its net cash usage in 2014, excluding revenue from the potential launch of M356 and milestones earned from the Baxter biosimilars collaboration, would average approximately $26 million per quarter.

Momenta Pharmaceuticals Inc. to Report Q3, 2014 Results on Nov 05, 2014

Momenta Pharmaceuticals Inc. announced that they will report Q3, 2014 results at 10:00 AM, US Eastern Standard Time on Nov 05, 2014

Momenta Pharmaceuticals Inc., Q3 2014 Earnings Call, Nov 05, 2014

Momenta Pharmaceuticals Inc., Q3 2014 Earnings Call, Nov 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LZ1:GR €9.34 EUR +0.113

LZ1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LZ1.
View Industry Companies
 

Industry Analysis

LZ1

Industry Average

Valuation LZ1 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOMENTA PHARMACEUTICALS INC, please visit www.momentapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.